Additional Methodological Details Participants
The target population was smokers from the London area, UK. Inclusion criteria for the study were: written informed consent; aged 18 65 years; smoked 10 or more cigarettes per day for the past year; generally in good health; motivated to quit smoking; English speaker. Exclusion criteria were: previous hypersensitivity to SJW; chronic disease; history of dependence on alcohol or a non-nicotine substance within the past year; current diagnosis of major depressive episode or a history of panic disorder, psychosis, bipolar disorder or eating disorders; pregnancy; lactation; women of child-bearing potential; current use of tobacco products other than cigarettes; current use of antidepressant agents; current use of regular prescription medication; current use of other smoking cessation treatments; use of NRT or SJW within previous 6 months; current participation in other research projects.
Setting, recruitment, screening and follow-up
The principal investigator who ran all aspects of the study was a pharmacist (JB; the "study pharmacist"). A physician (DW) was responsible for overseeing the study. All appointments were held in a private consulting room in a community pharmacy in North London, UK. The study began during 2000 and 12-month follow-up appointments were completed during 2002.
Potential participants were recruited using several approaches: advertisements were placed in newspapers regional to the pharmacy; information leaflets were placed in the pharmacy, along with a window display on smoking cessation which mentioned the study; local radio interviews were given. In each case, where possible, a telephone number for the SJW Information Centre (SJWIC), an industry-sponsored venture, was provided for volunteers to call for further information. Staff at the SJWIC followed a standard operating procedure which was to send out a patient information leaflet (PIL) to enquirers. The PIL provided details of the study, information on SJW, and instructed volunteers to telephone the study pharmacist for an initial screening interview. During this interview, which lasted around 15 minutes, the study pharmacist discussed smoking cessation, including NRT, answered volunteer's questions about the study, and checked the majority of inclusion and exclusion criteria using the volunteer's stage in the 'Stage of Change' cyclical model of behavioural change [1] as a guide in assessing the volunteer's motivation to quit.
Volunteers who met the initial screening criteria were given an appointment with the study pharmacist. Volunteers who did not meet the study criteria were given general smoking cessation advice and had no further involvement with the study.
At the first appointment, the study pharmacist repeated the procedure undertaken during the telephone screening interview, and checked additional inclusion/exclusion criteria.
Volunteers who met all eligibility criteria for the study gave written informed consent and were then enrolled into the study. A standard letter was sent to the participant's general practitioner (GP) if consent for this was given. After enrolment, data were collected on:
participants' characteristics and their smoking behaviour, including their Fagerstrom Test for Nicotine Dependence (FTND) score (a measure of dependence on nicotine); body weight; exhaled air carbon monoxide concentration (using an EC-50 Smokerlyser breath carbon monoxide monitor; Bedfont Instruments, Bedfont Scientific Ltd, Upchurch, Kent); and saliva cotinine concentration. Saliva samples were collected using Salivettes and sent immediately by first class post in biological sample collection boxes to Covance Laboratories Limited (Harrogate, UK) where they were stored frozen awaiting analysis using a validated assay. A target quit date for smoking cessation at least 2 weeks from the date of the current appointment was agreed with the participant; participants were 4 4 instructed to continue smoking as normal during this period. The study pharmacist dispensed the next consecutively numbered pre-randomised box of study medication and gave motivational/behavioural support [see Intervention], explained to the participant how to complete the study diary, and arranged the first follow-up appointment. This recruitment/enrolment visit lasted about one hour.
The study pharmacist telephoned participants 3 days after their target quit date to determine smoking status and to give encouragement and support. At the 4-week and 3-month follow-up visits after the target quit date, the study pharmacist collected the previous study diary, checked compliance by counting numbers of remaining SJW extract tablets (4-week and 3-month visits only), asked participants about their smoking status, and measured body weight, exhaled air carbon monoxide concentration and collected a saliva sample for analysis of cotinine concentration. Data collected at follow-up visits were recorded on pre-designed forms.
Participants recorded any adverse events in the study diaries, and the study pharmacist asked the participant about adverse events at each study visit (or telephone call for nonattendees). Participants were provided with telephone numbers to call in case of any serious adverse event. Any serious adverse events were reported to the medicines regulatory authority, ethics committee and manufacturer as necessary within 24 hours of receipt.
Participants who did not attend follow-up appointments were telephoned to make another appointment. Participants who continued not to attend or who otherwise indicated that they no longer wanted to take part in the study were sent an 'exit' questionnaire by post to determine their reason(s) for withdrawing from the study, their main reason for initially wanting to take part in the study, how, if at all, they thought the study could be improved, and a self-report of smoking status. A follow-up questionnaire was sent to nonresponders.
Intervention
Bulk supplies of tablets of dried extract of SJW herb (LI 160) in blister packaging were organised by Lichtwer Pharma UK Ltd and provided free of charge by Lichtwer Pharma GmbH [Berlin, Germany] . All tablets were from a single batch (Batch number: 00020600; expiry date: 28-02-2002). Quality control documents were provided by Lichtwer Pharma GmbH. Blisters were dispensed into the appropriate pack sizes and labelled by the study pharmacist.
Subjects were randomised to receive one 300 mg tablet each morning or 300 mg twice daily, beginning one week before a target quit date and continuing for 12 weeks afterwards. SJW was dispensed to participants in 2 instalments: a 5-week supply at the enrolment visit to cover administration for one week before and for 4 weeks after the target quit date, and an 8-week supply at the first follow-up visit (4 weeks post target quit date) to cover treatment to 3 months after the target quit date.
As motivational/behavioural support is an important component of any smoking cessation/abstinence programme, all participants received general smoking cessation advice and motivational support from the study pharmacist who had undertaken training in smoking cessation skills provided by the College of Pharmacy Postgraduate Education, UK, before the study began. At the enrolment visit, motivational/behavioural support was 6 6 given for about 20 minutes and comprised general tips on stopping smoking, in addition to discussion of the participant's particular concerns about smoking and stopping smoking.
This included, for example, identifying and building on participants' reasons (for example, health concerns and cost) for wanting to stop smoking, identifying participants' 'weak' areas and helping them plan coping strategies, and giving positive messages. Participants were encouraged to use the 2-week period before their target quit date as a preparation period. At follow-up visits (4 weeks and 3 months after the target quit date for the treatment phase of the study), support comprised reinforcement of general advice, along with more focused discussion depending on each participant's needs and smoking status for about 20 minutes.
Sample size
There were no previous studies of SJW in smoking cessation and, as this was an uncontrolled study, a formal sample size calculation was not possible. As 6-month quit rates obtained with NRT are between 10 and 20%, and as a high drop-out rate (around 50%) was considered likely, the aim was to recruit 200 participants. 
